Warning over off-label use

TGA cautions health practitioners about the off-label use of SGLT2 inhibitors, after reports associated with diabetic ketoacidosis The TGA is reminding health professionals about the risk of diabetic ketoacidosis with the off-label use of sodium glucose co-transporter 2 (SGLT2) inhibitors. While the medicines are approved for use in patients with type 2 diabetes mellitus (T2DM)